Cobra Biologics, international CDMO of biologics and pharmaceuticals, and Touchlight, a London-based emerging biotech with a novel enzyme technology for large scale production of DNA, are collaborating on a project to optimize the manufacture of Adeno-Associated Virus (AAV) vectors used in the delivery of gene therapy treatments. The collaboration aims to evaluate a platform for the safe and rapid production of AAV vectors, using Touchlight’s next generation dbDNA constructs, in conjunction with...